Maxcyte, Inc.
MXCT Nasdaq· Services-Commercial Physical & Biological Research
Last close · Oct 27, 2026
$1.54
KIRA · Stoqly’s AI analyst, in plain words
- Maxcyte, Inc. had $33.0M of revenue in fiscal 2025, down 14.5% on the year before. Over five years, revenue changed +4.8% a year on average.
- Its operating margin was −157.1%, down 24.6 pts: of every 100 in sales, about −157 is left after running the business.
- Maxcyte, Inc. lost $44.6M in fiscal 2025.
- Free cash flow was −$36.2M in fiscal 2025, −109.5% of revenue.
Market cap
$165M
P/E
—
Revenue
$33.0M
Net income
−$44.6M
Free cash flow
−$36.2M
Operating margin
−157.1%
Maxcyte, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−14.5%
No. Sales fell 14.5% last year.
Does it make a profit?
−135.1%
No. It lost money last year.
Does profit turn into cash?
−109.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Maxcyte, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- MAXCYTE, INC.
- CIK
- 0001287098
Maxcyte, Inc. · MXCT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $33.9M | $44.3M | $41.3M | $38.6M | $33.0M |
| Revenue growth | 29.5% | 30.6% | −6.7% | −6.4% | −14.5% |
| Gross margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Operating margin | −53.7% | −61.8% | −117.0% | −132.5% | −157.1% |
| Net income | −$19.1M | −$23.6M | −$37.9M | −$41.1M | −$44.6M |
| Net margin | −56.3% | −53.3% | −91.8% | −106.3% | −135.1% |
| Diluted EPS | −$0.21 | −$0.23 | −$0.37 | −$0.39 | −$0.42 |
| Cash | |||||
| Cash from operations | −$10.7M | −$14.8M | −$21.7M | −$27.6M | −$34.4M |
| Capital expenditure | $3.8M | $18.5M | $3.7M | $1.7M | $1.8M |
| Free cash flow | −$14.5M | −$33.3M | −$25.4M | −$29.3M | −$36.2M |
| FCF margin | −42.8% | −75.1% | −61.5% | −75.8% | −109.5% |
| Share count change | 30.5% | 12.2% | 1.5% | 1.5% | 1.5% |
| Debt and strength | |||||
| Cash and short-term investments | $255M | $227M | $168M | $154M | $103M |
| Shareholders' equity | $263M | $254M | $232M | $206M | $171M |
| Current ratio | 17.3x | 16.4x | 10.7x | 10.9x | 8.3x |
| Interest coverage | −3,368.3x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −12.9% | −9.1% | −15.6% | −18.7% | −23.6% |
| Return on tangible equity | −7.3% | −9.3% | −16.3% | −19.9% | −26.1% |
| Piotroski F-score | 3 | 2 | 2 | 3 | 2 |
| Altman Z'' | 17.1 | 11.4 | 7.6 | 6.4 | 3.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Maxcyte, Inc. · MXCT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.54 a share, the company is worth $165M.
Source: SEC EDGAR XBRL filings (CIK 0001287098). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.